The NEJM authors' claim that mammography does not conserve many lives through early detection of tumors is false. According to National Tumor Institute data, since mammography screening became widespread in the mid-1980s, the U.S. Breast malignancy death rate, unchanged for the prior 50 years, offers dropped well over 30 %. A study published in Malignancy Epidemiology, Biomarkers & Prevention shows mammography screening cuts the risk of dying from breast cancer nearly in half. A recent study published in Cancers showed that a lot more than 70 % of the ladies who died from breasts cancer within their 40s at major Harvard teaching hospitals were among the 20 % of women who weren’t being screened.ETC and Siena Biotech’s molecular inhibitors may enhance the prognosis for an extremely significant number of cancer patients, considering that gastric cancer is the 4th most common tumor in the globe and the next leading cause of cancer death. Gastric tumor is also one of the most common in Singapore , with over 600 cases diagnosed each year. ‘ETC is focused on translating early-stage scientific discoveries into useful applications,’ said Prof Alex Matter, CEO of ETC and leader of the research group that discovered the 1st targeted anti-cancer drug, Gleevec. ‘Leveraging on our technological know-how and the market experience of Siena Biotech, we expect our partnership to spark fresh breakthroughs for cancer study. We especially appreciate the energy of collaboration in the powerful arena of cancer drug discovery.’ Related StoriesMD Anderson research reveals why chemotherapy medicines not effective for many pancreatic cancer patientsInner hearing damage human brain warnings from nerve cellsSausages With Antioxidants From Berries TO AVOID CancerLarge molecule to take care of bone diseases SIgN and Siena Biotech are jointly creating a novel monoclonal antibody applicable to bone diseases such as for example osteoporosis.